# AST-3424

Source: https://onco.cc/drugs/ast-3424/  
OnCo record `ast-3424` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

AST-3424 is an experimental small molecule AKR1C3-activated prodrug from Ascentawits Pharmaceuticals, in phase 2 trials for hepatocellular carcinoma, advanced solid tumours and T-cell acute lymphoblastic leukaemia and other cancers.

## Summary

AST-3424 (OBI-3424, TH-3424) is a small molecule AKR1C3-activated prodrug (DNA alkylator) from Ascentawits Pharmaceuticals, with OBI Pharma as partner and Zhejiang Hisun Pharmaceutical as partner. A nitrogen mustard prodrug that the enzyme AKR1C3 cleaves to an active molecule that alkylates and cross-links DNA, so it is aimed at tumours with high AKR1C3. Its furthest stage is phase 2, for hepatocellular carcinoma, advanced solid tumours, T-cell acute lymphoblastic leukaemia and T-cell lymphoblastic lymphoma. ClinicalTrials.gov registers it in 4 studies linked below. Registry: NCT07310173 phase 2b vs regorafenib in AKR1C3-high HCC, recruiting (sponsor Zhejiang Hisun); NCT06239155 phase 1/2 active, not recruiting (sponsor Ascentawits); NCT04315324 phase 1/2 in T-ALL/T-LBL (SWOG/NCI) active, not recruiting; OBI Pharma's NCT03592264 phase 1/2 terminated. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-11-03
- Also known as: OBI-3424; TH-3424
- Tags: pipeline; ctgov-ingest
- Code: AST-3424
- Modality: Small molecule AKR1C3-activated prodrug (DNA alkylator)
- Mechanism: A nitrogen mustard prodrug that the enzyme AKR1C3 cleaves to an active molecule that alkylates and cross-links DNA, so it is aimed at tumours with high AKR1C3.

## Sources

- Ascentawits Pharmaceuticals: pmc.ncbi.nlm.nih.gov: https://pmc.ncbi.nlm.nih.gov/articles/PMC8332853/
- Ascentawits Pharmaceuticals: pmc.ncbi.nlm.nih.gov: https://pmc.ncbi.nlm.nih.gov/articles/PMC8332853/
- Ascentawits Pharmaceuticals: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT04315324
- ClinicalTrials.gov: trials of AST-3424: https://clinicaltrials.gov/search?intr=AST-3424

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Ascentawits Pharmaceuticals](https://onco.cc/companies/ascentawits-pharmaceuticals/), [OBI Pharma](https://onco.cc/companies/obi-pharma/), [Zhejiang Hisun Pharmaceutical](https://onco.cc/companies/zhejiang-hisun/)
- trials: [A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors](https://onco.cc/trials/nct06239155/), [A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors](https://onco.cc/trials/nct03592264/), [Phase IIb Study of AST-3424 in Patients With AKR1C3-high Expressing Advanced Hepatocellular Carcinoma](https://onco.cc/trials/nct07310173/), [Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)](https://onco.cc/trials/nct04315324/)
- targets: [AKR1C3](https://onco.cc/targets/akr1c3/)

---
JSON: https://onco.cc/api/v1/entities/ast-3424.json